expert roundtables

Discussing Safety and Tolerability of Disease-Modifying Antirheumatic Drugs With Patients
Rheumatology

Discussing Safety and Tolerability of Disease-Modifying Antirheumatic Drugs With Patients

expert roundtables
By John R. P. Tesser, MD; Jonathan Kay, MD; Leonard H. Calabrese, DO; Vibeke Strand, MD, MACR, FACP
Role of Age and Fitness in Selecting Treatment for Chronic Lymphocytic Leukemia
Oncology

Role of Age and Fitness in Selecting Treatment for Chronic Lymphocytic Leukemia

expert roundtables
By Anthony R. Mato, MD, MSCE; Jan A. Burger, MD, PhD; Jennifer R. Brown, MD, PhD
Clinical Impact of Non–Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Rheumatology

Clinical Impact of Non–Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

expert roundtables
By John R. P. Tesser, MD; Jonathan Kay, MD; Leonard H. Calabrese, DO; Vibeke Strand, MD, MACR, FACP
Interpreting Chronic Lymphocytic Leukemia Prognostic Markers in the Novel Treatment Era
Oncology

Interpreting Chronic Lymphocytic Leukemia Prognostic Markers in the Novel Treatment Era

expert roundtables
By Anthony R. Mato, MD, MSCE; Jan A. Burger, MD, PhD; Jennifer R. Brown, MD, PhD
Rheumatology

Use of Rheumatoid Arthritis Biomarkers to Stratify Patients

expert roundtables
By Alan L. Epstein, MD; Vibeke Strand, MD, MACR, FACP
Load More